Aprea Therapeutics Inc (NASDAQ: APRE) made new highs on Wednesday to close with gains of 16.32%. This came after the company presented results from its U.S. Phase lb/II clinical trial of APE-246, and Azacitidine in patients suffering from TP53 mutant Myelodysplastic Syndrome and from Acute Myeloid Leukemia. The presentation was done at the 2019 American Society of Hematology annual meeting in Orlando, Florida.
In the presentation, the company announced that there was a response rate of 88% in 33 MDS patients, and they had a 61% remission rate. The trial had a median of 10.8 months follow up period, and patients had a median response rate of 8.4 months in a CR duration of 7.3 months. The company also announced that, 52% of those evaluated discontinued therapy and opted to pursue a stem cell transplant.
On top of that, the median survival for the 55 enrolled patients stood at 10.8 months. The median overall survival in the responding patients was higher than that of non-responders. The company also noted that, adverse effects during the trial were mainly graded ½. The more adverse grade 3+ events happened in about 20% of the patients and were mainly limited to cytopenias infections and were in line with the patient’s hematopoietic malignancies.
The company also announced that eligible patients in the phase lb/II clinical trial included HMA-naïve, TP53, mutated MDS and oligoblostic acute myeloid leukemia. The primary endpoint from this trial was safety, while the secondary endpoints included PFS, IWS 2006 and OS and evaluation of clonal suppression.
From the charts, the stock opened the day at $31.20 and traded between $30.77and $36.50 before closing at $35.70. Volumes in the day stood at 161.99k.
About Aprea Therapeutics Inc
Aprea Therapeutics Inc is a biopharma company that develops and sells cancer treatments. The company’s lead treatment candidate is APR-246 a potential treatment for hematologic malignancies. It is headquartered in Boston, Massachusetts.